Analyzing Code Rebel (OTCMKTS:CDRBQ) and Simulations Plus (NASDAQ:SLP)

Code Rebel (OTCMKTS:CDRBQ) and Simulations Plus (NASDAQ:SLP) are both computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, earnings and profitability.

Profitability

This table compares Code Rebel and Simulations Plus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Code Rebel	N/A	N/A	N/A
Simulations Plus	-78.63%	11.62%	10.84%

Analyst Ratings

This is a summary of recent ratings for Code Rebel and Simulations Plus, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Code Rebel	0	0	0	0	0.00
Simulations Plus	1	5	4	0	2.30

Simulations Plus has a consensus price target of $24.40, indicating a potential upside of 65.38%. Given Simulations Plus’ stronger consensus rating and higher probable upside, analysts plainly believe Simulations Plus is more favorable than Code Rebel.

Earnings & Valuation

This table compares Code Rebel and Simulations Plus”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Code Rebel	N/A	N/A	N/A	N/A	N/A
Simulations Plus	$70.01 million	4.24	$9.95 million	($3.15)	-4.68

Simulations Plus has higher revenue and earnings than Code Rebel.

Insider & Institutional Ownership

78.1% of Simulations Plus shares are held by institutional investors. 19.4% of Simulations Plus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Code Rebel has a beta of 94.39, meaning that its share price is 9,339% more volatile than the S&P 500. Comparatively, Simulations Plus has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.

Summary

Simulations Plus beats Code Rebel on 8 of the 10 factors compared between the two stocks.

About Code Rebel

Code Rebel Corporation operates as a software and information technology (IT) services company. It operates in two segments, Software and IT Services. The Software segment develops, markets, and licenses interactive remote application terminal services solution (iRAPP). The iRAPP allows personal computers users to use applications on a single Mac remote desktop simultaneously via the iRAPP client or any standard compliant remote desktop protocol client. This segment offers iRAPP client-side products for Mac OS X and Windows applications; iRAPP terminal server products, including iRAPP-single-user remote desktop and iRAPP-TS multiple-user terminal server for Mac OS X applications; and iRAPP access products, such as iRAPP Load Balancer and iRAPP Gateway. The IT Services segment provides Independent Software Vendor relationships (ISVs)/channel partner platforms, which provide project management, application, and technical consulting, as well as database administration for implementing projects and managed-services engagements; and professional services consulting that implements, upgrades, and maintains software packages those ISVs offer to their clients. Code Rebel Corporation was founded in 2007 and is based in Kahului, Hawaii.

About Simulations Plus

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.